Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 244 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: eicosapentaenoic acid Clear all
Completed No phase listed Observational Accepts healthy volunteers

Understanding Fish Consumption Habits During Pregnancy

NCT01178398
View directory record Official record
Conditions
Nutrition
Interventions
Not listed
Lead sponsor
Harvard Pilgrim Health Care
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 14, 2026, 10:32 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Effects of Omega-3 Fatty Acid Supplementation in Acne Patients

NCT01764308
View directory record Official record
Conditions
Acne
Interventions
Omega-3, Placebo
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 14, 2026, 10:32 AM EDT
Completed Phase 3 Interventional Results available

Effects of Docosahexaenoic Acid (DHA) on Fetal Cardiac Outcomes

NCT01007110
View directory record Official record
Conditions
Pregnancy
Interventions
DHA, Placebo
Dietary Supplement · Other
Lead sponsor
University of Kansas
Other
Eligibility
16 Years to 35 Years · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 14, 2026, 10:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Study Products Containing Varying Quantities of Docosahexaenoic Acid (DHA)

NCT01174134
View directory record Official record
Conditions
Levels of DHA in the Blood
Interventions
Nutritional beverage
Other
Lead sponsor
Mead Johnson Nutrition
Industry
Eligibility
18 Months to 36 Months
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2011 · Synced Oct 14, 2026, 10:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dietary Essential Fatty Acid Regulation of Omega-3 HUFA Metabolism; Satiety and Body Composition

NCT01251887
View directory record Official record
Conditions
Weight Gain, Healthy Subjects, Obesity, Women
Interventions
Linoleic Acid, Docosahexaenoic Acid, Eicosapentaenoic Acid
Dietary Supplement
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 14, 2026, 10:32 AM EDT
Active, not recruiting Phase 2 Interventional

Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression

NCT05774665
View directory record Official record
Conditions
Treatment Resistant Depression, Inflammation, Overweight
Interventions
Omega 3, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 14, 2026, 10:32 AM EDT
Recruiting Not applicable Interventional

Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants

NCT05380401
View directory record Official record
Conditions
Premature
Interventions
Enfamil® DHA & ARA Supplement for Special Dietary Use
Dietary Supplement
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Up to 36 Weeks
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 14, 2026, 10:32 AM EDT
Terminated Phase 4 Interventional

A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults

NCT04505098
View directory record Official record
Conditions
Covid19, Atherosclerosis, Cardiovascular Diseases, Upper Respiratory Tract Infections
Interventions
Icosapent ethyl
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
50 Years and older
Enrollment
39,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 14, 2026, 10:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Omega-3 Fatty Acids in Ambient Air Pollution Exposure in Healthy Adults

NCT02921048
View directory record Official record
Conditions
Health Effects of Ambient Air Pollution
Interventions
omega-3 fatty acids
Dietary Supplement
Lead sponsor
U.S. EPA Human Studies Facility
Federal
Eligibility
25 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 14, 2026, 10:32 AM EDT
Completed Phase 1 Interventional Results available

DHA For The Treatment of Pediatric Concussion Related to Sports Injury

NCT01903525
View directory record Official record
Conditions
Concussion, Mild Traumatic Brain Injury
Interventions
Docosahexaenoic acid (DHA), Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
14 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 14, 2026, 10:32 AM EDT
Not listed Phase 4 Interventional

Pilot Study of Lovaza (Omega 3 Fatty Acids) to Improve Cardiac Antioxidant/Anti-inflammatory Profile Before Cardiac Surgery

NCT01046604
View directory record Official record
Conditions
Mitral Valve Regurgitation, Left Atrium Dilatation and Hypertrophy, Mitochondrial Dysfunction in the Heart, Cardiomyocyte Apoptosis, Cardiac Inflammation
Interventions
Lovaza group
Drug
Lead sponsor
East Carolina University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2013 · Synced Oct 14, 2026, 10:32 AM EDT
Completed Phase 2 Interventional Results available

COVID-19 Anosmia Study

NCT04495816
View directory record Official record
Conditions
Anosmia, Covid19
Interventions
Omega-3 Fatty Acid Supplement, Placebo/Control
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 14, 2026, 10:32 AM EDT
Completed Early Phase 1 Interventional

Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects

NCT02538484
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole, Fish Oil
Drug · Dietary Supplement
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 14, 2026, 10:32 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Vitamin D and Omega-3 Fatty Acids on Infectious Diseases and hCAP18 (VITAL Infection)

NCT01758081
View directory record Official record
Conditions
Infections, Human Cathelicidin Antimicrobial Peptide (hCAP-18)
Interventions
vitamin D3, omega-3 fatty acids (fish oil), Vitamin D3 placebo, fish oil placebo
Dietary Supplement · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
25,874 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 14, 2026, 10:32 AM EDT
Completed Phase 3 Interventional Results available

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

NCT01492361
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
AMR101, Placebo, Statin therapy
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
45 Years and older
Enrollment
8,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
176
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 154 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 14, 2026, 10:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Vascepa to Accelerate Lipoprotein Uptake and Elimination

NCT03885661
View directory record Official record
Conditions
Lipid Disorder, Triglycerides High, Dyslipidemias
Interventions
Icosapent Ethyl 1000 MG [Vascepa]
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 14, 2026, 10:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Study of OMEGA-3 and Vitamin D in High-Dose in Type I Diabetic Patients

NCT03406897
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Hypoglycemia, Diabetes Mellitus, Diabetes, Autoimmune
Interventions
Cholecalciferol, Omega 3 fatty acid
Drug
Lead sponsor
Rodolfo Alejandro
Other
Eligibility
6 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 14, 2026, 10:32 AM EDT
Completed Phase 3 Interventional

TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease

NCT00146211
View directory record Official record
Conditions
Huntington Disease
Interventions
Ethyl-EPA (Miraxion™)
Drug
Lead sponsor
Amarin Neuroscience Ltd
Industry
Eligibility
35 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Oct 14, 2026, 10:32 AM EDT
Completed Phase 1 Interventional

Effect of DHA Supplements on Macular Function in Patients With Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy

NCT00060749
View directory record Official record
Conditions
Macular Degeneration
Interventions
Docosahexaenoic Acid (DHA) Dietary Supplement
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 14, 2026, 10:32 AM EDT
Recruiting Not applicable Interventional

Concentration of n-3 PUFA Monohydroxylated Derivatives in Adults With Obesity After n-3 PUFA Supplementation.

NCT06991296
View directory record Official record
Conditions
Obesity
Interventions
SPM Active®
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 14, 2026, 10:32 AM EDT
Completed No phase listed Observational

PET Imaging of DHA Metabolism

NCT00074503
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 14, 2026, 10:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Assessment of DHA On Reducing Early Preterm Birth

NCT02626299
View directory record Official record
Conditions
Preterm Birth
Interventions
Docosahexaenoic acid - 800mg/day, Docosahexaenoic acid - 200mg/day, Placebo
Drug · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
3
States / cities
Kansas City, Kansas • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 14, 2026, 10:32 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Synergistic Activity of Human Milk Nutrients and Infant Cognition

NCT03838536
View directory record Official record
Conditions
Breastfeeding, Exclusive
Interventions
Whole Egg Powder, Egg White Powder
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Months to 35 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 14, 2026, 10:32 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Impact of COX2 on Sera Biomarkers From Obese Subjects

NCT02062255
View directory record Official record
Conditions
Breast Cancer Survivors
Interventions
Aspirin, Omega 3 FFA
Drug · Dietary Supplement
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Female only
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 14, 2026, 10:32 AM EDT